Лучшие больницы для «Peyronie's Disease Treatment» в Дубай, ОАЭ

The total cost of Peyronie's Disease Treatment depends primarily on the chosen intervention. In India, at JCI- and NABH-accredited partner hospitals, a single intralesional CCH (Xiaflex) injection cycle (outpatient) costs approximately USD 1,500–2,500; a full 4-cycle programme ranges USD 4,000–6,500 inclusive of repeat visits. Penile plication surgery (Nesbit/16-dot) costs USD 2,000–3,500 all-in (surgeon, anaesthesia, 1–2 day hospital stay, standard medications). Plaque incision/excision with grafting ranges USD 3,000–5,500, and inflatable penile prosthesis (IPP) implantation with modelling is USD 4,500–6,500 depending on device brand. In the UAE (Dubai/Abu Dhabi), at JCI-accredited and DHA/DoH-licensed centres, the equivalent costs are substantially higher reflecting premium infrastructure and operational costs: CCH injection cycle USD 3,500–5,000; full 4-cycle programme USD 10,000–14,000; plication surgery USD 4,500–7,000; grafting surgery USD 6,000–10,000; IPP implantation USD 8,000–14,000. India is typically 40–60% more affordable than the UAE for identical procedures performed by fellowship-trained andrologists. All GAF Healthcare packages are itemised transparently—there are no hidden facility or interpretation fees. Cost savings on treatment in India or the UAE versus the USA, UK, or Australia frequently exceed 60–75% even after accounting for international flights and accommodation.

The fit-to-fly timeline depends on the specific treatment received. For intralesional injection therapy (CCH/Xiaflex or verapamil): each injection cycle is an outpatient procedure; patients can typically fly home 5–7 days after the final injection of each cycle, once local swelling and bruising have resolved and there are no signs of skin tear or corporal injury. Since a full CCH programme involves 4 cycles at 6-week intervals, patients travelling for a single cycle can return home within one week of treatment. For penile plication surgery (Nesbit/16-dot technique): hospital stay is 1–2 days; most patients are cleared to fly 10–14 days post-operatively, once wound integrity is confirmed and they are comfortable in a seated aircraft position. For plaque incision/excision with grafting: hospital stay is 2–3 days; the fit-to-fly window is typically 2–3 weeks post-operatively due to the more extensive surgical dissection, the need for wound inspection, and confirmation of graft take. For inflatable penile prosthesis (IPP) implantation: hospital stay is 2–3 days; patients are generally cleared to fly 2–3 weeks post-operatively, after a wound check and initial device cycling instruction. A formal fit-to-fly certificate, required by most airlines for passengers within 4 weeks of major surgery, is issued by the treating GAF-affiliated surgeon before departure. Patients are advised to wear compression stockings on the flight and ambulate regularly to reduce DVT risk. Final guidance is always individualised based on the patient's healing progress at their pre-departure clinical review.

Success rates for Peyronie's Disease Treatment are intervention-specific and must be understood in the context of what 'success' means clinically—functional straightening sufficient for satisfactory intercourse, not complete elimination of the plaque. For collagenase CCH (Xiaflex) injection therapy: the IMPRESS I & II Phase III pivotal trials (the largest RCTs in PD pharmacotherapy) demonstrated a mean penile curvature improvement of approximately 34% (vs. 18% placebo), with ~40% of men achieving a clinically meaningful response (≥20° improvement); combined with penile traction therapy, real-world response rates approach 50–60%. For penile plication (Nesbit/16-dot): surgical straightening to <15° residual curvature is achieved in 85–95% of appropriately selected patients, with patient satisfaction rates of 80–85% at 2-year follow-up; the trade-off is predictable penile shortening of 0.5–2.0 cm. For plaque incision/excision with grafting: curvature correction rates of 85–95% are reported in high-volume centres; however, de novo erectile dysfunction occurs in 5–25% depending on pre-operative vascular status, and long-term recurrence of curvature affects 5–10% of patients at 5 years. For inflatable penile prosthesis (IPP) implantation with modelling: this procedure delivers the highest combined success rate in men with both PD and significant ED—curvature correction exceeding 85% and patient satisfaction rates consistently above 90% in long-term series, making it the most definitive single intervention for this patient profile. Overall, when patients are correctly selected and treated by fellowship-trained andrologists at high-volume centres—as coordinated by GAF Healthcare—the probability of achieving functional, intercourse-compatible penile straightening is 70–90% across the treatment spectrum.